What is Lion TCR?
Lion TCR is a pioneering biotechnology firm specializing in the development of advanced immunotherapies, with a primary focus on T cell receptor (TCR)-T cell therapy. Their therapeutic strategies are aimed at combating challenging diseases such as HBV-related hepatocellular carcinoma and other prevalent viral infections across Asia. By leveraging the patient's own immune system, Lion TCR's proprietary therapy has demonstrated robust clinical safety and efficacy, leading to substantial improvements in survival rates for liver cancer patients. The company distinguishes itself with the world's largest patented TCR library, encompassing a broad spectrum of HLA types, and operates a cutting-edge GMP production facility essential for clinical-grade therapeutic manufacturing. Lion TCR is actively engaged in ongoing clinical trials and strategic research collaborations to further enhance its pipeline of advanced therapies.
How much funding has Lion TCR raised?
Lion TCR has raised a total of $20M across 1 funding round:
Other Financing Round
$20M
Other Financing Round (2018): $20M, investors not publicly disclosed
What's next for Lion TCR?
The substantial enterprise-level funding Lion TCR has garnered, particularly the recent strategic investment, positions the company for accelerated growth and expanded clinical development. This capital infusion is expected to fuel further research into their groundbreaking TCR-T cell therapies, potentially enabling broader market penetration and the advancement of new treatment protocols for viral infections and associated oncological conditions. Lion TCR's commitment to expanding its clinical trial footprint and forging new research partnerships will be critical in translating its extensive library and manufacturing capabilities into widespread patient benefit.
See full Lion TCR company page
